Evidence map›Paper›PMID 41947654›Full record

ArticleActa dermato-venereologica2026

Predicting Melanoma Impact on the Swedish Healthcare System from the Adult Population Using Machine Learning on Registry Data.

Martin Gillstedt, Lena Stempfle, John Paoli, Fredrik D Johansson, Sam Polesie

Abstract read
In one paragraph

Article in Acta dermato-venereologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Martin GillstedtDepartment of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Dermatology and Venereology, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden. martin.gillstedt@gu.se.ORCID 0000-0001-5033-5421
Lena StempfleDepartment of Computer Science and Engineering, Chalmers University of Technology and University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-6580-3942
John PaoliDepartment of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Dermatology and Venereology, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.ORCID 0000-0003-1326-8535
Fredrik D JohanssonDepartment of Computer Science and Engineering, Chalmers University of Technology and University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-4323-3715
Sam PolesieDepartment of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Dermatology and Venereology, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden; Center for Digital Health, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.ORCID 0000-0002-5398-6200

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma incidence has increased in Western countries over the past 50 years, leading to significant healthcare costs. In Sweden, comprehensive healthcare registries enable large-scale prediction studies using machine learning. Several machine learning models were evaluated to predict melanoma diagnoses using Swedish registry data, assessing the added value of diagnostic and medication data beyond demographics. The study included all adults in Sweden with continuous residency for 9.5 years (n = 6,036,186). The outcome was a melanoma diagnosis, including melanoma in situ, recorded within 5 years after the index date (31 December 2014). Predictors included age, sex, income, education, marital status, region of birth, diagnoses, and dispensed drugs. Models tested were logistic regression, gradient boosting, random forests, and a neural network. A total of 38,582 individuals (0.64%) developed melanoma. The gradient boosting model using all predictors performed best, with an area under the receiving operating characteristics curve (AUC) of 0.735 (95% confidence interval [CI], 0.725-0.746). When diagnosis and medication data were excluded, AUC dropped to 0.681 (95% CI: 0.670-0.691). The findings highlight that including healthcare codes improves predictive performance, and demonstrate the utility of Swedish registries for computational phenotyping. This approach may support early detection of melanoma and targeted follow-up.

Indexed as

Machine LearningMelanomaSkin NeoplasmsAdultAgedBoosting Machine Learning AlgorithmsClassification AlgorithmsFemaleHumansIncidenceMaleMiddle AgedPrediction AlgorithmsPredictive Learning ModelsPredictive Value of TestsRandom Forest

Identifiers

PMID41947654
PMCPMC13069475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.